This is a Study to Evaluate the Safety and Tolerability of the Study Drug ABL001, and to Determine the Maximum Tolerated Dose and/or Recommended Phase 2 Study Dose of ABL001
Clinical trial NCT03292783 · COMPLETED
Trial details
- NCT number
- NCT03292783
- Sponsor
- ABL Bio, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-18
- Primary completion
- 2021-03-02
- Enrollment
- 45
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.